Corporate insiders filed a range of buy and sell disclosures with the Securities and Exchange Commission on Wednesday, detailing purchases by company directors and executives as well as large-scale disposals by major stakeholders. The activity touched companies across multiple sectors including software, industrial safety, energy, automotive, semiconductors and biotechnology. Below is a company-by-company accounting of the most significant filings reported for the day.
Top insider buys
Universal Safety Products, Inc. (NASDAQ: UUU) - Director Ault Milton C III reported a sequence of purchases totaling $72,808. According to the Form 4 filing, Ault made acquisitions on March 30 and March 31. On March 30, Ault purchased 2,008 shares at a weighted average price of $5.5433, with individual execution prices ranging from $5.4888 to $5.54535, and additionally bought 500 shares at a weighted average price of $5.3896, with prices from $5.35 to $5.4381 per share. The filings show further purchases on March 31: 5,000 shares at a weighted average price of $5.8406, with traded prices between $5.75 and $5.90, another block of 5,000 shares at $5.8452, and 100 shares at $5.5364.
GitLab Inc. (NASDAQ: GTLB) - Chief Executive Officer William Staples disclosed two purchases of the company’s Class A Common Stock on March 31, 2026, together valued at $128,342. The transactions executed at prices ranging from $21.30 to $21.65. In the first transaction Staples acquired 5,069 shares at a weighted average price of $21.30, with individual prices spanning $20.62 to $21.56. The second transaction consisted of 941 shares at a weighted average price of $21.65, with execution prices ranging from $21.62 to $21.69. The filing notes that the stock was trading near its 52-week low of $20.20 at the time, having fallen 55% over the prior year. The filing also cites an InvestingPro analysis indicating GitLab appears undervalued at current levels and that analysts expect the company to reach profitability within the year despite recent losses.
Advanced Flower Capital Inc. (NASDAQ: AFCG) - Leonard M. Tannenbaum, a director and holder of 10% of the company’s stock, reported buying 29,040 shares of common stock on March 31, 2026, per the Form 4 filing. The shares were purchased at $2.76 apiece, for a total reported consideration of $80,150. The reported trade prices ranged from $2.67 to $2.81. The filing notes that the transaction occurred amid recent upward momentum in the share price, which returned 10% over the prior week. Following the purchase, Tannenbaum directly owns 6,426,175 shares of Advanced Flower Capital. The article reiterates an InvestingPro view that AFCG appears undervalued at current levels and highlights the company’s 7% dividend yield. The filing also references Advanced Flower Capital’s recent financial disclosure for the fourth quarter of 2025, where the company missed analyst expectations with earnings per share of -$0.12 versus a forecasted $0.03 and revenue of $5.19 million against an anticipated $5.46 million.
Team Inc. (NYSE: TISI) - Director Anthony R Horton disclosed multiple purchases of common stock in filings with the SEC. On March 20, 2026, Horton acquired 10,000 shares at $14.44 per share. He later made an additional purchase on March 30, 2026, buying 3,000 shares at $16.19 per share. The Form 4s report these transactions as direct purchases of common stock.
Vitesse Energy, Inc. (NYSE: VTS) - Director Dan O’Leary purchased 10,000 shares of common stock on March 31, 2026, at a price of $18.56 per share, for a total reported transaction value of $185,600. The filing notes that the purchase occurred while the stock was trading near its 52-week low of $17.44. The company is described as offering a dividend yield of 9.64%. Following the purchase, O’Leary directly owns 33,789 shares of Vitesse Energy. The article restates market information that the company has an approximate $722 million market capitalization and that analyst price targets on the name range from $19 to $28.
Top insider sells
Fermi Inc. (NASDAQ: FRMI) - Caddis Holdings, LP, identified in filings as a ten percent owner, reported selling 11,000,000 shares of common stock for aggregate proceeds of about $56,268,500. The sales were executed in two transactions on March 30 and March 31, 2026. On March 30, 2026, Caddis Holdings, LP sold 9,000,000 shares at a weighted average price of $5.0213 per share, with individual prices ranging from $4.9286 to $5.346 per share, representing roughly $45,191,700 in proceeds for that tranche. The filings highlight that the stock has experienced notable volatility, declining 19% over the prior week and 83% over the prior year.
Tesla, Inc. (NASDAQ: TSLA) - Director Kathleen Wilson-Thompson sold 20,008 shares of common stock on March 30, 2026, for approximately $9.27 million, with execution prices ranging from $352.833 to $366.855 per share. The filing also records that on the same day Wilson-Thompson exercised options to acquire 40,000 shares of Tesla common stock at $14.99 per share, for a total exercise value of $599,600. The article notes the stock’s prevailing trading price of $381.31 and cites an InvestingPro observation that Tesla’s shares are overvalued relative to its Fair Value estimate. The filing reiterates that Tesla trades at a price-to-earnings ratio of 352, emphasizing the premium valuation reflected by that metric.
Monolithic Power Systems Inc. (NASDAQ: MPWR) - Executive Vice President and General Counsel Saria Tseng disclosed sales of 25,094 shares on March 30, 2026, with aggregate proceeds of approximately $25.9 million. The reported execution prices ranged from $1,000.81 to $1,041.12 per share. The filing states the stock has appreciated 94% over the previous year and was trading at $1,119.49 at the time of the report. The filing also notes an InvestingPro assessment that shares may be overvalued relative to the company’s Fair Value estimate. The transactions were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2025.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) - Ryan Savitz, serving as EVP, CFO and CBO, reported selling 91,847 shares of common stock on March 31, 2026, for total proceeds of $9.5 million. The execution prices ranged from $78.33 to $85.54. The filing additionally discloses that Savitz exercised options on the same day to acquire 114,367 shares of Dianthus Therapeutics common stock, with option exercise prices of $8.44 and $17.88, and that the aggregate cost to exercise those options was $1,342,857.
CoreWeave, Inc. (CRWV) - Chief Development Officer Brannin McBee sold Class A Common Stock on March 30, 2026, realizing approximately $9.9 million in proceeds. The sales occurred at prices ranging from $67.67 to $75.19 per share, which the filing notes are below the then-current market price of $78.44. The Form 4 details multiple tranches: 33,090 shares at a weighted average price of $67.6666; 20,603 shares at a weighted average price of $68.7648; 23,907 shares at a weighted average price of $69.6511; 12,600 shares at a weighted average price of $70.5452; 4,800 shares at a weighted average price of $71.6821; 2,200 shares at a weighted average price of $72.6445; 1,300 shares at a weighted average price of $74.1185; and 1,500 shares at a weighted average price of $74.8667. The filings observe that the stock had fallen 11.54% over the prior week, per InvestingPro data.
Context and takeaways
The day’s filings illustrate a mixed pattern of insider activity: company insiders in several smaller-cap names and a major software CEO added to positions, while substantial sales were disclosed at companies ranging from a newly public micro-cap to established large-cap technology and automotive issuers. The largest single disclosed disposal came from Caddis Holdings, LP at Fermi, while material buys were recorded at GitLab and Universal Safety Products. Some filings included contextual market references such as 52-week lows or recent share-price momentum, and several entries quoted InvestingPro conclusions about valuation or analyst expectations.
Investors often monitor insider filings for signals on how management and significant owners view near-term prospects, but the filings alone do not provide a definitive indicator of future performance. Purchases can reflect confidence, opportunistic accumulation at depressed prices or other motives; sales can reflect personal liquidity needs, option exercises, or rebalancing - facts that are not always apparent from the filings themselves. Several transactions were executed under pre-arranged plans, and some included option exercises paired with share sales.
Bottom line
Wednesday’s slate of insider transactions spanned a broad cross-section of market capitalizations and sectors. The disclosures underline divergent insider behavior across software, industrial safety, energy, automotive, semiconductors and biotechnology names. Market participants who track insider transactions should consider these filings alongside fundamental metrics, technical trends and other company-specific developments to form a fuller view of a name’s near-term risk-reward profile.